Recent IPO activity remains robust into October 2026, with multiple companies pricing offerings or advancing through the pipeline amid a selective but open window. Biotech issuers such as Iambic Therapeutics and TRex Bio have set terms for deals targeting $125–150 million, while Centinel Spine and Lycia Therapeutics filed fresh S-1s; several others, including Retension Pharmaceuticals, are slated for near-term trading. Broader 2026 volume has already exceeded 250 U.S. listings year-to-date, though volatility prompted postponements like Oura’s and mixed aftermarket performance for recent deals such as Accelevation. Key catalysts ahead include additional October and November pricings, with larger AI-related names largely deferred toward 2027. Market-implied sentiment reflects sustained but cautious capital-market access supported by equity valuations and sector-specific demand.